Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $22.91: Risk below floor (2.8 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 3.91; Below-average business quality.
Arcutis Biotherapeutics is a commercial-stage biopharma focused on dermatological diseases, with four FDA-approved products all under the ZORYVE brand (roflumilast): cream 0.3% for plaque psoriasis, foam for seborrheic dermatitis and scalp/body psoriasis, and creams 0.15% and... Read more
Sell if holding. Engine safety override at $22.91: Risk below floor (2.8 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 3.91; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 6.0/10, moderate confidence.
Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductZORYVE10-K Item 1A: 'Our business is dependent on the successful commercialization of ZORYVE and the development, regulatory approval, and commercialization of our current product candidates.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·2 ceiling hits
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $22.91: Risk below floor (2.8 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 3.91; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $21.47. Score 6.0/10, moderate confidence.
Take-profit target: $30.23 (+32.2% upside). Prior stop was $21.47. Stop-loss: $21.47.
Concentration risk — Product: ZORYVE; Risk below floor (2.8 < 3.0).
Arcutis Biotherapeutics, Inc. trades at a P/E of N/A (forward 18.6). TrendMatrix value score: 7.2/10. Verdict: Sell.
14 analysts cover ARQT with a consensus score of 4.1/5. Average price target: $35.
What does Arcutis Biotherapeutics, Inc. do?Arcutis Biotherapeutics is a commercial-stage biopharma focused on dermatological diseases, with four FDA-approved...
Arcutis Biotherapeutics is a commercial-stage biopharma focused on dermatological diseases, with four FDA-approved products all under the ZORYVE brand (roflumilast): cream 0.3% for plaque psoriasis, foam for seborrheic dermatitis and scalp/body psoriasis, and creams 0.15% and 0.05% for atopic dermatitis. Net loss was $16.1M in 2025 with $1.14B accumulated deficit. The Kowa co-promotion agreement was terminated January 2026.